These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1106 related articles for article (PubMed ID: 26769228)

  • 41. Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.
    Finelli C; Follo MY; Stanzani M; Parisi S; Clissa C; Mongiorgi S; Barraco M; Cocco L
    Curr Pharm Des; 2016; 22(16):2349-57. PubMed ID: 26960675
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
    Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS
    Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.
    Li X; Chang C; He Q; Xu F; Zhang Q; Wu L; Su J; Zhang X; Zhou L; Wu D; Song L; Zhang Z
    Leuk Res; 2013 Nov; 37(11):1516-21. PubMed ID: 24084368
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetic abnormalities and pathophysiology of MDS.
    Hosono N
    Int J Clin Oncol; 2019 Aug; 24(8):885-892. PubMed ID: 31093808
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Life after hypomethylating agents in myelodysplastic syndrome: new strategies.
    Santini V
    Curr Opin Hematol; 2015 Mar; 22(2):155-62. PubMed ID: 25603477
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.
    Bouchla A; Thomopoulos TP; Papageorgiou SG; Apostolopoulou C; Loucari C; Mpazani E; Pappa V
    Epigenomics; 2021 Jul; 13(14):1129-1143. PubMed ID: 34291653
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?
    Cook MR; Karp JE; Lai C
    EJHaem; 2022 Feb; 3(1):301-313. PubMed ID: 35846202
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2014 Jan; 89(1):97-108. PubMed ID: 24464505
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel therapies in low- and high-risk myelodysplastic syndrome.
    Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
    Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
    [No Abstract]   [Full Text] [Related]  

  • 51. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group.
    Cseh AM; Niemeyer CM; Yoshimi A; Catala A; Frühwald MC; Hasle H; van den Heuvel-Eibrink MM; Lauten M; De Moerloose B; Smith OP; Bernig T; Gruhn B; Kulozik AE; Metzler M; Olcay L; Suttorp M; Furlan I; Strahm B; Flotho C
    Br J Haematol; 2016 Mar; 172(6):930-6. PubMed ID: 26766110
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
    Merkel DG; Nagler A
    Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Azacitidine for the treatment of myelodysplastic syndrome.
    Cataldo VD; Cortes J; Quintás-Cardama A
    Expert Rev Anticancer Ther; 2009 Jul; 9(7):875-84. PubMed ID: 19589026
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
    Silverman LR; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An update on the treatment of myelodysplastic syndromes.
    Kurtin SE; Demakos EP
    Clin J Oncol Nurs; 2010 Jun; 14(3):E29-44. PubMed ID: 20529786
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.
    Keating GM
    Drugs; 2009; 69(17):2501-18. PubMed ID: 19911860
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
    Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
    J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.
    Martín I; Villamón E; Abellán R; Calasanz MJ; Irigoyen A; Sanz G; Such E; Mora E; Gutiérrez M; Collado R; García-Serra R; Vara M; Blanco ML; Oiartzabal I; Álvarez S; Bernal T; Granada I; Xicoy B; Jerez A; Calabuig M; Diez R; Gil Á; Díez-Campelo M; Solano C; Tormo M;
    Br J Haematol; 2021 Aug; 194(4):708-717. PubMed ID: 34296432
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study.
    Hatoum HT; Lin SJ; Buchner D; Kim E
    Curr Med Res Opin; 2011 Jun; 27(6):1255-62. PubMed ID: 21554144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.